Antiagregantes plaquetarios y cirugía oral: retirar o no retirar, esa es la cuestión / Antiplatelet therapy and oral surgery: to discontinue or not, that is the question

Las enfermedades cardiovasculares constituyen una de las patologías sistémicas más prevalentes en el mundo occidental. Muchos pacientes cardiópatas han tenido un episodio coronario agudo y están siendo tratados con antiagregantes plaquetarios. La terapia con estos fármacos puede suponer un reto para el odontólogo, que debe enfrentarse a un importante dilema: o mantener el fárma co, con el consiguiente riesgo hemorrági co, o retirarlo, con la posibilidad de que se produzcan complicaciones tromboembólicas, suponiendo un riesgo para la vida del paciente. Por ello, los odontólogos deberíamos conocer cuál debe ser el manejo de este tipo de pacientes ante la perspectiva de realizar un procedimiento quirúrgico en la cavidad oral o incluso una simple extracción dentaria. Los objetivos de esta revisión narrativa son, en primer lugar, recordar la fisiología plaquetaria y los mecanismos de forma ción del trombo plaquetario; en segundo lugar, profundizar en los mecanismos de acción de los diferentes fármacos antia gregantes plaquetarios; y, en tercer lugar, ya que no existen guías clínicas al res pecto, realizar un abordaje crítico de las pautas existentes para el manejo odonto lógico de este tipo de pacientes, en aras de prevenir la aparición de posibles com plicaciones, no solo locales, sino, lo que es más importante, complicaciones sisté micas. En estos casos, antes de retirar la terapia antiagregante, convendría sope sar el riesgo hemorrágico versus el riesgo de generar un nuevo episodio tromboem bólico, como puede ser la trombosis dstent o la recidiva del accidente coronario agudo, eventos que podrían poner en riesgo la vida del paciente (AU)

Cardiovascular disease is one of the most prevalent systemic pathologies worldwide; those patients usually have had an acute coronary event which is treated with antiplatelet therapy. These drugs represent a challenge for the dentist, who must face a major dilemma: either maintain the drug, with the consequent bleeding risk, or withdraw it, with the possibility of thromboembolic complications, entailing a risk to the patient’s life. Therefore, dentists should know how to manage patients treated with these drugs when performing a surgical procedure or even a simple tooth extraction. The objectives of this narrative review are, firstly, to recall platelet physiology and the mechanisms of platelet thrombus formation; secondly, to go more deeply into the mechanisms of action of the different antiplatelet drugs; and thirdly, since there are no clinical guidelines on this topic, to critically review the existing guidelines related to the dental management, in order to prevent the appearance of possible complications, not only local, but more importantly, systemic complications. In these cases, before interrupting antiplatelet therapy,the risk of bleeding should be evaluated against the risk of generating a new thromboembolic episode, such as stent thrombosis or recurrence of the acute coronary accident, events that could put the patient’s life at risk (AU)

Effect of the use of platelet concentrates on new bone formation in alveolar ridge preservation: a systematic review, meta-analysis, and trial sequential analysis.

OBJECTIVES: To investigate the histomorphometric changes occurring in alveolar ridge preservation (ARP) based on the use of different plasma concentrates (PCs) in randomized clinical trials (RCT). There is controversy whether the placement of PCs in ARP is effective in the formation of new bone. MATERIALS AND METHODS: A systematic review search was conducted in PubMed, Scopus, Web of Science, and Cochrane Database to answer the PICO question: In patients undergoing tooth extraction followed by ARP, do PCs alone in the post-extraction socket in comparison with spontaneous healing improve new vital bone formation percentage in histomorphometric analysis after more than 10 weeks? The risk of bias was assessed and a meta-analysis was conducted. RESULTS: Of 3809 results, 8 studies were considered suitable for inclusion. A total of 255 teeth were extracted in 250 patients. Regarding the PCs used, ARP was performed with platelet- and leukocyte-rich fibrin (L-PRF) in 120 sockets, and with pure platelet-rich plasma (P-PRP) in 31 sockets and 104 sockets were controlled. PCs improved new bone formation in ARP with respect to the spontaneous healing group (SMD = 1.77, 95%C.I. = 1.47-2.06, p-value < 000.1). There were no differences between the different PCs (L-PRF and P-PRP). CONCLUSION: The results of this meta-analysis support the efficacy of the use of PCs in new bone formation in ARP. With respect to the different types of PCs studied, no differences were observed. CLINICAL RELEVANCE: When planning implant surgery after tooth extraction, treatment with PCs should be considered for ARP. Any PC increases new bone formation compared to spontaneous healing.

Plasma rich in growth factors (PRGF) and leukocyte-platelet rich fibrin (L-PRF): comparative release of growth factors and biological effect on osteoblasts.

PURPOSE: To compare the release of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-I) and interleukin 1ß (IL-1ß) of plasma rich in growth factors (PRGF) and leucocyte platelet-rich fibrin (L-PRF) and to evaluate their biological implication in osteoblasts. METHODS: Blood from 3 healthy volunteers was processed into PRGF, immediate L-PRF (L-PRF 0') and L-PRF 30 min after collection (L-PRF-30') and a control group. Growth factors release were analyzed at 7 times by ELISA. Cell proliferation, collagen-I synthesis and alkaline phosphatase activity were assessed in primary cultures of human osteoblasts. RESULTS: A slower controlled release of IGF-I, VEGF and PDGF was observed in the PRGF group at day 14. A higher synthesis of type I collagen was also quantified in PRGF. L-PRF released significantly higher amounts of IL-1ß, that was almost absent in the PRGF. CONCLUSIONS: The addition of leukocytes dramatically increases the secretion of proinflammatory cytokines, which are likely to negatively influence the synthesis of type I collagen and alkaline phosphatase (ALP) by osteoblasts.

Surgical complications in zygomatic implants: A systematic review

BACKGROUND: The use of zygomatic implants in the prosthetic rehabilitation of the patient with severe maxillary bone atrophy is another therapeutic alternative, not exempt from complications. The main objective of this review is to analyze and describe the most frequent surgical complications associated with the use of zygomatic implants. MATERIAL AND METHODS: An electronic database search on PubMed, along with a manual search, without taking into account date nor language, was undertaken by two observers, selecting studies that comprised a study period from 6 to 12 months, any type of clinical trial, and series that included a follow-up and/or review period during the aforementioned margin, that mentioned at least two types of complications. RESULTS: Out of the initial search that yielded 455 studies, 67 were considered potentially relevant for the present study, out of which 14 were finally selected. Out of the most frequent surgical complications, sinusitis (3,9%) and failure in osseointegration (2,44%) are highlighted. CONCLUSIONS: The analysis of the results shows that the most frequent complications are sinusitis and failure in osseointegration of the zygomatic implant. However, a standardised data collection system for the data on complications is needed